Arvinas stock
ARVNNASDAQArvinas, Inc., HealthcareISIN US04335A1051
37Score 37 out of 100, Weak
Price and trend
33 / 100
Price history
−34% in one yearThe chart shows daily closes over 8 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 27% below it.
Since May 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 44).
The price is 50% below its 52-week high. Largest decline in 8 years: 94% (July 2021 to May 2025).
Chart figures for advanced users
- SMA 50$7.67
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$9.43
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)44
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$6.41
- The lowest closing price of the last twelve months.
- Resistance$13.83
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Arvinas, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $449.88M, is number 249 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $262.6M (down 0.3% year on year) and a loss of $80.8M.
- For fiscal 2026, analysts expect on average revenue of $279.8M (up 6.6%) and adjusted earnings per share of $0.07.
Show more
- MEQIRI Score 37 out of 100 (Weak): rank 573 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 58.9% a year since 2020, Biotechnology median 19.4%.Growth 70
- More cash than debtCash $558.4M, financial debt $7.6M.Stability 73
Weaknesses
- DilutionShare count up 64% since 2020.Capital allocation 18
- Loss-makingLoss of $9.5M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$159.8M over the last 12 months.Fundamentals 17
Its standout strengths are stability and growth, while capital allocation and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
One-off effect in revenue
In the quarter to 30 Jun 2026, revenue of $249.7M was about 8 times the usual level. P/E, margin, growth and score for the last twelve months depend on it.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue fell 0.3% on the prior year. Revenue has grown strongly since 2016, at around 50% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 98%, operating −44%, net −31%. Last 12 months: net −3%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 23 Feb 2027in 102 days
- Last reported
- 3 Nov 2026EPS reported −$0.82 (expected −$0.92)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 274.9% since 15 Oct 2026.
- Earnings per share
- $0.07+274.9%
- Revenue
- $279.8M−5.5%
- Earnings per share
- −$3.17+4.4%
- Revenue
- $47.76M−24.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +4.2%No financial guidance changed: cash runway still extends into the second half of 2028, and the next clinical trials are now expected to begin in 2027.
“Interactions with the agencies are ongoing, and we look forward to updating you on our timing for initiating our next clinical trials, which we now expect to begin in 2027.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 4 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 4 insiders sold, $87,475 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Loomis David KSale
9 Nov 2026, VP, Chief Accounting Officer
- Shares
- 232
- Price
- $6.36
- Value
- $1,475
- Saik AndrewSale
24 Jun 2026, Chief Financial Officer
- Shares
- 5,696
- Price
- $8.16
- Value
- $46,474
- Cacace Angela MSale
17 Jun 2026, Chief Scientific Officer
- Shares
- 2,576
- Price
- $7.60
- Value
- $19,565
Show 1 more
- Teel RandySale
21 May 2026, President and CEO
- Shares
- 2,209
- Price
- $9.04
- Value
- $19,962
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Arvinas
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 37
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- MiMedx GroupMDXG $472.8M37
- Hansa BiopharmaHNSA.ST $472.24M47
- Oculis HoldingOCS $462.99M30
- Gyre TherapeuticsGYRE $455.95M35
- Avalo TherapeuticsAVTX $445.24M34
- CytomX TherapeuticsCTMX $444.73M31
- Relmada TherapeuticsRLMD $443.75M37
- BlossomHill TherapeuticsBLSM $431.56M41
ETFs that hold Arvinas
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.04% | 0.40% | €1.5B |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.03% | 0.35% | €1.25B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.28B |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.22B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.5B |
| Invesco Global Buyback Achievers UCITS ETFBBCK | 0.01% | 0.39% | €190.04M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.00% | 0.45% | €1.54B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.00% | 0.30% | €964.08M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 29 Feb 2024)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.